Caplan Syndrome
|
disease |
Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Respiratory Tract Diseases; Occupational Diseases
|
Disease or Syndrome
|
1
|
|
0.010 |
None |
1.000 |
1 |
|
1979 |
1979 |
Malignant essential hypertension
|
disease |
Cardiovascular Diseases
|
Disease or Syndrome
|
1
|
|
0.010 |
None |
1.000 |
1 |
|
1998 |
1998 |
Birdshot chorioretinitis
|
disease |
|
Disease or Syndrome
|
1
|
|
0.010 |
None |
1.000 |
1 |
|
2004 |
2004 |
Post-tuberculous reactive arthritis
|
disease |
Infections; Musculoskeletal Diseases
|
Disease or Syndrome
|
1
|
|
0.010 |
None |
1.000 |
1 |
|
2010 |
2010 |
Seronegative juvenile chronic arthritis
|
disease |
Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Immune System Diseases
|
Disease or Syndrome
|
1
|
|
0.010 |
None |
1.000 |
1 |
|
1989 |
1989 |
Lumbar meningomyelocele
|
disease |
Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nervous System Diseases
|
Congenital Abnormality
|
1
|
|
0.010 |
None |
< 0.001 |
1 |
|
1984 |
1984 |
Scotoma, Arcuate
|
phenotype |
Pathological Conditions, Signs and Symptoms; Eye Diseases; Nervous System Diseases
|
Finding
|
1
|
|
0.100 |
None |
|
0 |
|
|
|
HYPERSENSITIVITY SYNDROME, CARBAMAZEPINE-INDUCED, SUSCEPTIBILITY TO
|
phenotype |
|
Finding
|
1
|
1
|
0.100 |
None |
|
0 |
1
|
|
|
Blind-spot enlargment
|
phenotype |
|
Finding
|
1
|
|
0.100 |
None |
|
0 |
|
|
|
Aortitis Syndrome
|
disease |
Skin and Connective Tissue Diseases; Cardiovascular Diseases
|
Disease or Syndrome
|
2
|
|
0.010 |
None |
1.000 |
1 |
|
1982 |
1982 |
Erythroderma, Maculopapular
|
disease |
Skin and Connective Tissue Diseases
|
Disease or Syndrome
|
2
|
|
0.300 |
None |
1.000 |
1 |
|
2006 |
2006 |
Parakeratosis Variegata
|
disease |
Skin and Connective Tissue Diseases
|
Disease or Syndrome
|
2
|
|
0.300 |
None |
1.000 |
1 |
|
2006 |
2006 |
EBV-Related Hodgkin Lymphoma
|
disease |
Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases
|
Neoplastic Process
|
2
|
|
0.010 |
None |
1.000 |
1 |
|
2010 |
2010 |
Severe cutaneous adverse reactions (SMQ)
|
phenotype |
|
Classification
|
2
|
2
|
0.100 |
None |
1.000 |
1 |
1
|
2019 |
2019 |
Encephalitis Lethargica
|
disease |
Infections; Nervous System Diseases
|
Disease or Syndrome
|
3
|
|
0.010 |
None |
1.000 |
1 |
|
1982 |
1982 |
Insulin C-peptide measurement
|
phenotype |
|
Laboratory Procedure
|
3
|
7
|
0.100 |
None |
1.000 |
1 |
1
|
2018 |
2018 |
Halothane Hepatitis
|
disease |
Digestive System Diseases; Chemically-Induced Disorders
|
Disease or Syndrome
|
3
|
|
0.010 |
None |
1.000 |
1 |
|
1985 |
1985 |
Erosive osteoarthrosis
|
disease |
Musculoskeletal Diseases
|
Disease or Syndrome
|
3
|
|
0.010 |
None |
1.000 |
1 |
|
1989 |
1989 |
Advanced Synovial Sarcoma
|
disease |
|
Neoplastic Process
|
3
|
|
0.010 |
None |
1.000 |
1 |
|
2019 |
2019 |
Photoreceptor layer loss on macular OCT
|
phenotype |
|
Finding
|
3
|
|
0.100 |
None |
|
0 |
|
|
|
Presumed ocular histoplasmosis syndrome
|
disease |
Infections
|
Disease or Syndrome
|
4
|
|
0.010 |
None |
1.000 |
1 |
|
2003 |
2003 |
Poliomyelitis, paralytic
|
disease |
|
Disease or Syndrome
|
4
|
1
|
0.010 |
None |
1.000 |
1 |
|
1979 |
1979 |
Cicatrix
|
phenotype |
Pathological Conditions, Signs and Symptoms
|
Pathologic Function
|
4
|
2
|
0.100 |
None |
1.000 |
1 |
1
|
2019 |
2019 |
Vitreous floaters
|
phenotype |
|
Finding
|
4
|
1
|
0.100 |
None |
|
0 |
|
|
|
Scarred macula
|
phenotype |
Pathological Conditions, Signs and Symptoms
|
Acquired Abnormality
|
4
|
|
0.100 |
None |
|
0 |
|
|
|